Novabay Pharmaceuticals (NBY) 0.61 $NBY Next Week In

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Novabay Pharmaceuticals (NBY) 0.61 $NBY

Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 28.32 (-0.74), MDT: 78.02 (+0.36), RARE: 62.06 (-0.83), PFE: 34.25 (+0.10), SUPN: 11.35 (-0.11), NRX: 7.41 (-0.12), LLY: 76.12 (+1.90), GSK: 48.81 (+0.60), SVA: 5.02 (+0.03), BLRX: 2.06 (+0.03), AMPH: 14.74 (+0.30), CHRS: 26.46 (-2.27), JNJ: 102.40 (+0.71), GNVC: 3.16 (+0.07), CYCC: 0.98 (+0.02), AZN: 72.70 (+1.80), DPRX: 14.00 (+0.49), TEVA: 62.10 (+0.55), NBY: 0.61 (-0.02)

The National Necrotizing Fasciitis Foundation Names NovaBay's NeutroPhase as its Official "Flesh Eating Disease" Wound Cleanser
PR Newswire - Tue Mar 17, 6:00AM CDT
The National Necrotizing Fasciitis Foundation (NNFF) today announced the NNFF has named NeutroPhase®, a wound cleanser made by NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), the official wound cleanser of the NNFF.
NBY: 0.61 (-0.02)

NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth
Business Wire - Mon Mar 16, 6:00AM CDT
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today provided an update on its commercial launch of Avenova(TM).
NBY: 0.61 (-0.02)

NovaBay Pharmaceuticals Signs Avenova and NeutroPhase Distribution Agreements
Business Wire - Mon Mar 09, 6:00AM CDT
--Agreements expand distribution of NovaBay's breakthrough products to more markets around the world
NBY: 0.61 (-0.02)

InsiderInsights.com Daily Round Up 3/5/15: OAS, CRR, NBY, SIR
InsiderInsights - at Seeking Alpha - Fri Mar 06, 11:45AM CST

CST: 43.38 (-0.31), SIR: 25.57 (+0.73), CRR: 32.05 (+0.52), WETF: 22.23 (+1.22), SAM: 277.36 (+9.46), QTWO: 21.65 (+0.09), MOH: 64.89 (-0.24), HTWO: 9.70 (-0.11), VCRA: 9.97 (-0.08), WIW: 11.27 (+0.01), HAFC: 20.79 (+0.04), SGEN: 38.86 (-0.83), MOSY: 1.94 (+0.06), CUDA: 38.33 (-1.64), SQBG: 10.06 (+0.09), ASGN: 38.80 (+0.13), HBI: 34.18 (-0.16), FTNT: 35.31 (-0.16), OAS: 13.80 (-0.16), NBY: 0.61 (-0.02)

NovaBay raises $4.9M in a private placement
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 9:30AM CST

NBY: 0.61 (-0.02)

NovaBay to distribute prescription Avenova for blepharitis and dry eye to pharmacies across the US through Cardinal Health
M2 - Tue Jan 27, 3:07AM CST
Biopharmaceutical company NovaBay Pharmaceuticals (NYSE MKT:NBY) said on Monday that it has entered into a nationwide distribution agreement for Avenova with Cardinal Health (CAH), which delivers prescription drugs to retail pharmacies, hospitals, mail-order facilities, physician offices and surgery centres across the US.
NBY: 0.61 (-0.02)

NovaBay signs Avenova distribution agreement with Cardinal Health
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 6:12AM CST

MCK: 229.94 (+4.19), CAH: 91.25 (+1.33), NBY: 0.61 (-0.02)

NovaBay Signs Avenova Distribution Agreement with Cardinal Health
Business Wire - Mon Jan 26, 6:02AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that it has signed a nationwide distribution agreement with Cardinal Health (NYSE: CAH), which delivers prescription drugs and many other products to retail pharmacies, hospitals, mail-order facilities, physician offices, surgery centers and other facilities across the U.S.
MCK: 229.94 (+4.19), CAH: 91.25 (+1.33), NBY: 0.61 (-0.02)

NovaBay Will Expand Marketing for Avenova At Arab Health 2015
ACCESSWIRE - Fri Jan 23, 6:00AM CST
NovaBay Pharmaceuticals will expand marketing and seek partners for Avenova at the world's largest healthcare conference
NBY: 0.61 (-0.02)

NovaBay Management and Key Industry Opinion Leaders to Hold Investment Community Conference Call Today, January 21st, 2015, at 12:00 p.m. ET
Business Wire - Wed Jan 21, 6:00AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company developing and commercializing non-antibiotic anti-infective products, will host an investment community conference call. Management will discuss the Company's refined business focus on products for the eye care market announced January 7, 2015, and sales force expansion announced January 20, 2015.
NBY: 0.61 (-0.02)

NovaBay Expands Sales Force for Avenova
Business Wire - Tue Jan 20, 1:38PM CST
--NovaBay management and key industry opinion leaders to hold an investment community conference call tomorrow, January 21st, at 12:00 p.m. Eastern time
NBY: 0.61 (-0.02)

NovaBay revamps strategy to focus on Eye Care
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:36AM CST

NBY: 0.61 (-0.02)

NovaBay Announces New Business Strategy Focusing on Products for Eye Care
Business Wire - Wed Jan 07, 6:00AM CST
--Seeking strategic alternatives for wound care, urology and dermatology assets
NBY: 0.61 (-0.02)

NovaBay Rebrands Its i-Lid Cleanser as Avenova
Business Wire - Mon Jan 05, 6:01AM CST
NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of topical non-antibiotic anti-infective products, announces the rebranding of its i-Lid Cleanser with Neutrox(TM) as Avenova(TM) with Neutrox. This name change, effective immediately, helps NovaBay to differentiate prescription Avenova from other products marketed as eye cleaners, in particular over-the-counter (OTC) products not intended for continuous daily use.
NBY: 0.61 (-0.02)

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders
at The Street - Wed Dec 17, 10:42AM CST
Stocks with insider trader activity include NBY, WPX and KTOS
WPX: 11.09 (+0.16), KTOS: 5.82 (+0.10), NBY: 0.61 (-0.02)

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders
at The Street - Tue Dec 16, 10:38AM CST
Stocks with insider trader activity include EVTC, CRM and NBY
EVTC: 22.61 (+0.01), NBY: 0.61 (-0.02), CRM: 67.69 (-1.19)

NovaBay Executive Officers Report Insider Buying of 143,000 Common Shares to the SEC
ACCESSWIRE - Tue Dec 16, 6:00AM CST
EMERYVILLE, CA / ACCESSWIRE / December 16, 2014 / NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) reported that between December 2 and 12, 2014, NovaBay's CEO, CFO and Senior Vice President have filed Form 4's with the Security and Exchange Commission reporting their combined purchases of 143,000 shares of NovaBay common stock in open market purchases. During one the company's infrequent and brief open trading windows for insiders, NovaBay's CEO, Dr. Ron Najafi, purchased over 113,000 shares, the Company's CFO, Tom Paulson, purchased 20,000 shares and NovaBay's Senior Vice President of Ophthalmology, Dr. David Stroman, purchased 10,000 shares. Shares were purchased at prices ranging between $0.60 and $0.71; prices the Officers believe are a substantial discount to NovaBay's potential long term value.
NBY: 0.61 (-0.02)

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders
at The Street - Fri Dec 12, 10:15AM CST
Stocks with insider trader activity include CGIX, NBY and BIOA
BIOA: 9.00 (+0.03), NBY: 0.61 (-0.02), CGIX: 7.85 (-0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading